Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138943 | 1.00 | CXCR2 (0.33) | CXCR2ALDH1A1KDM4ECXCR1TAAR1 | |
| SCHEMBL4662901 | 1.00 | CXCR2 (0.33) | CXCR2ALDH1A1KDM4ECXCR1TAAR1 | |
| SCHEMBL5107989 | 0.91 | AOC3 (0.37) | HIF1A | |
| SCHEMBL5107986 | 0.91 | AOC3 (0.37) | HIF1A | |
| SCHEMBL5106848 | 0.90 | AOC3 (0.32) | KDM4E | |
| SCHEMBL5106851 | 0.90 | AOC3 (0.32) | KDM4E | |
| SCHEMBL4664676 | 0.89 | CXCR2 (0.34) | CXCR2ALDH1A1KDM4ECXCR1PPARG | |
| SCHEMBL4664608 | 0.89 | PDK1 (0.32) | CXCR2ALDH1A1KDM4ECXCR1PRKDC | |
| SCHEMBL4965043 | 0.89 | CTSA (0.33) | ALDH1A1KDM4E | |
| SCHEMBL4962050 | 0.89 | CTSA (0.33) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | CXCR2 4387/4885ALDH1A1 2588/4885KDM4E 3472/4885 |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | CXCR2 4046/4885ALDH1A1 76/4885KDM4E 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.